PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33852856-2 2021 The last step of de novo sphingolipid synthesis is the conversion of dihydroceramide to ceramide by dihydroceramide desaturase (human DEGS1; Drosophila Ifc). Sphingolipids 25-37 delta 4-desaturase, sphingolipid 1 Homo sapiens 134-139 33609744-8 2021 PI3K inhibition also affected the S1P receptors and gene expression of enzymes such as the dihydroceramide delta 4 desaturase (DEGS1) and sphingosine kinase 1 (SK1) in the de novo sphingolipid pathway. Sphingolipids 180-192 delta 4-desaturase, sphingolipid 1 Homo sapiens 127-132 31631013-3 2019 Here, we demonstrate distinct wiring of the sphingolipidome across the human hematopoietic hierarchy and find that genetic or pharmacologic modulation of the sphingolipid enzyme DEGS1 regulates lineage differentiation. Sphingolipids 44-56 delta 4-desaturase, sphingolipid 1 Homo sapiens 178-183 28988346-12 2018 In addition, the expression of specific enzymes of sphingolipid metabolism, dihydroceramide desaturase 1 and sphingomyelin synthase 1, was increased in the PBMCs of individuals with type 2 diabetes. Sphingolipids 51-63 delta 4-desaturase, sphingolipid 1 Homo sapiens 76-104 30620337-0 2019 Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. Sphingolipids 12-24 delta 4-desaturase, sphingolipid 1 Homo sapiens 36-41 30620338-5 2019 The blood sphingolipid profile in the patient showed a significant increase in dihydro sphingolipid species that was further recapitulated in patient-derived fibroblasts, in CRISPR/Cas9-derived DEGS1-knockout cells, and by pharmacological inhibition of DEGS1. Sphingolipids 10-22 delta 4-desaturase, sphingolipid 1 Homo sapiens 194-199 30620338-5 2019 The blood sphingolipid profile in the patient showed a significant increase in dihydro sphingolipid species that was further recapitulated in patient-derived fibroblasts, in CRISPR/Cas9-derived DEGS1-knockout cells, and by pharmacological inhibition of DEGS1. Sphingolipids 10-22 delta 4-desaturase, sphingolipid 1 Homo sapiens 253-258 30620338-5 2019 The blood sphingolipid profile in the patient showed a significant increase in dihydro sphingolipid species that was further recapitulated in patient-derived fibroblasts, in CRISPR/Cas9-derived DEGS1-knockout cells, and by pharmacological inhibition of DEGS1. Sphingolipids 87-99 delta 4-desaturase, sphingolipid 1 Homo sapiens 194-199 30620338-5 2019 The blood sphingolipid profile in the patient showed a significant increase in dihydro sphingolipid species that was further recapitulated in patient-derived fibroblasts, in CRISPR/Cas9-derived DEGS1-knockout cells, and by pharmacological inhibition of DEGS1. Sphingolipids 87-99 delta 4-desaturase, sphingolipid 1 Homo sapiens 253-258 31227640-5 2019 We identified a Hispanic ancestry-specific rare functional variant, L175Q, in delta 4-desaturase, sphingolipid 1 (DEGS1), a key enzyme in the pathway that converts dihydroceramide to ceramide. Sphingolipids 98-110 delta 4-desaturase, sphingolipid 1 Homo sapiens 114-119 18711209-8 2009 Celecoxib inhibited the dihydroceramide desaturase (DEGS) in vivo with an IC(50) of 78.9 +/- 1.5 muM and increased total Cer level about 2-fold, indicating an activation of sphingolipid biosynthesis. Sphingolipids 173-185 delta 4-desaturase, sphingolipid 1 Homo sapiens 52-56 26934645-10 2016 Therefore, we propose targeting androgen-independent prostate cancer cells with compounds that affect Des1/SK1 to modulate both de novo and sphingolipid rheostat pathways in order to induce growth arrest. Sphingolipids 140-152 delta 4-desaturase, sphingolipid 1 Homo sapiens 102-106 23547262-4 2013 In cells lacking Des1, the most common sphingolipids were replaced with dihydro forms lacking the double bond inserted by Des1. Sphingolipids 39-52 delta 4-desaturase, sphingolipid 1 Homo sapiens 17-21 23267130-1 2013 BACKGROUND: Dihydroceramide desaturase 1 (DES) is the enzyme responsible for converting dihydroceramide into ceramide in the de novo sphingolipid biosynthesis pathway. Sphingolipids 133-145 delta 4-desaturase, sphingolipid 1 Homo sapiens 12-40 28379228-1 2017 Dihydroceramide desaturase 1 (Des1) catalyzes the last step of ceramide synthesis de novo, thus regulating the physiologically relevant balance between dihydrosphingolipids and sphingolipids. Sphingolipids 159-172 delta 4-desaturase, sphingolipid 1 Homo sapiens 0-28 28379228-1 2017 Dihydroceramide desaturase 1 (Des1) catalyzes the last step of ceramide synthesis de novo, thus regulating the physiologically relevant balance between dihydrosphingolipids and sphingolipids. Sphingolipids 159-172 delta 4-desaturase, sphingolipid 1 Homo sapiens 30-34 22628619-4 2012 Lipidomic analysis of distribution and speciation of multiple lipid classes indicates an increase in phospholipids in SPTLC123-silenced cells, whereas DEGS1 depletion leads to the accumulation of sphingolipid intermediates, free fatty acids, and diacylglycerol. Sphingolipids 196-208 delta 4-desaturase, sphingolipid 1 Homo sapiens 151-156 34106748-7 2021 The efficiency of cell-cell fusion in DES1 knockout (KO) cells was at a level comparable to that in wild-type (WT) cells; however, the ratio of saturated sphinganine-based lipids to the total sphingolipids was higher in DES1 KO cells, compared to that in WT cells. Sphingolipids 192-205 delta 4-desaturase, sphingolipid 1 Homo sapiens 38-42 34106748-7 2021 The efficiency of cell-cell fusion in DES1 knockout (KO) cells was at a level comparable to that in wild-type (WT) cells; however, the ratio of saturated sphinganine-based lipids to the total sphingolipids was higher in DES1 KO cells, compared to that in WT cells. Sphingolipids 192-205 delta 4-desaturase, sphingolipid 1 Homo sapiens 220-224 35013382-6 2022 Further examination of the mechanisms behind these observations showed that JTE-013, at concentrations frequently used in the literature to target S1P2/4, inhibits several sphingolipid metabolic enzymes, including dihydroceramide desaturase 1 and both sphingosine kinases. Sphingolipids 172-184 delta 4-desaturase, sphingolipid 1 Homo sapiens 214-242 35560527-8 2022 Integration with transcriptome data identified candidate enzymes for IHC validation: Delta4-Desaturase, Sphingolipid 1 (DEGS1) which desaturates dihydroceramide to ceramide, and Delta5 and Delta6-Desaturases (fatty acid desaturases, FADS1 and FADS2), responsible for polyunsaturation. Sphingolipids 104-116 delta 4-desaturase, sphingolipid 1 Homo sapiens 120-125